|
Dr Paul Yeh will discuss the key to improving patient outcomes in blood cancer patients and how they evolve under therapeutic pressure from pre-malignant conditions and why it is vital in developing strategies to screen, prevent and treat these conditions.
Recent advances in genomic sequencing have significantly increased our ability to capture genetic information from patients to understand tumour evolution and heterogeneity. However, obtaining adequate and representative tissue for such analysis is often challenging and unfeasible due to the invasive nature of tissue biopsy.
This seminar will highlight Dr Yeh’s work on capturing genomic information from a minimally invasive liquid biopsy to provide insights into blood cancers. These will include the use of circulating tumour DNA (ctDNA) from plasma as a disease monitoring tool in haematologic malignancy. Additionally, he will present work using blood testing to provide novel understandings of the pre-malignant blood condition, clonal haematopoiesis.
This event will be held online via Zoom. Registrations are essential.
|
